Eli Lilly & Hims & Hers Health Announce Agreement To Expand Access To Zepbound & Foundayo
Nov 6 (Reuters) - Eli Lilly and Company LLY.N:
ELI LILLY: CO, HIMS & HERS HEALTH ANNOUNCED AGREEMENT TO HELP EXPAND ACCESS TO ZEPBOUND (TIRZEPATIDE) & FOUNDAYO (ORFORGLIPRON)
ELI LILLY: AGREEMENT GIVES PATIENTS PATH TO FDA-APPROVED TREATMENTS AT SELF-PAY PRICE THROUGH THE HIMS & HERS PLATFORM
ELI LILLY: SELF-PAY PRICING STARTS AT $149 PER MONTH FOR FOUNDAYO & $299 PER MONTH FOR ZEPBOUND
ELI LILLY: HIMS & HERS HAS COMMITTED NOT TO OFFER ACCESS TO COMPOUNDED COPIES OF LILLY’S GLP-1S IN FUTURE
Further company coverage: LLY.N